In short
Tadekinig Alfa, also known as recombinant human Interleukin-18 Binding Protein (r-hIL-18BP), is an investigational drug being studied in clinical trials for the treatment of rare autoinflammatory conditions. These trials focus on patients with NLRC4 mutations, XIAP deficiency, and cytokine release syndrome (CRS) related to CAR T cell therapy. The drug aims to block the action of interleukin-18 (IL-18), a key mediator in systemic inflammatory conditions, potentially offering new hope for patients with these challenging disorders.
At a glance
- Drug Name
- Tadekinig Alfa (r-hIL-18BP)
- Mechanism of Action
- Interleukin-18 binding protein that neutralizes IL-18
- Conditions Studied
- NLRC4 mutations, XIAP deficiency, CRS related to CAR T cell therapy
- Administration
- Subcutaneous injection
- Primary Outcomes
- Safety, tolerability, adverse events, immunogenicity, local tolerability
- Study Designs
- Open-label extension, randomized withdrawal, pilot study
- Duration
- Varies by study (26 weeks to 34 weeks)
- Key Measurements
- CRP, ferritin levels, mAIDAI score, prevention of flares, duration of response
What is Tadekinig Alfa?
Tadekinig alfa, also known as r-hIL-18BP or IL-18BP, is an innovative medication being studied for the treatment of rare inflammatory conditions. It is a type of protein called a recombinant human interleukin-18 binding protein. This means it's a laboratory-made version of a protein that naturally occurs in the human body.
What Conditions Does Tadekinig Alfa Treat?
Tadekinig alfa is being investigated for several rare conditions characterized by excessive inflammation in the body. These include:
- NLRC4-MAS (NLRC4 mutation-associated Macrophage Activation Syndrome): A genetic condition that causes the immune system to become overactive, leading to severe inflammation.
- XIAP Deficiency: A rare genetic disorder that affects the immune system and can cause a severe inflammatory condition called hemophagocytic lymphohistiocytosis (HLH).
- Cytokine Release Syndrome (CRS): A condition that can occur as a side effect of certain cancer treatments, particularly CAR T-cell therapy.
- HLH-like Syndrome: A severe inflammatory condition that can occur as a complication of other treatments or diseases.
How Does Tadekinig Alfa Work?
Tadekinig alfa works by binding to and neutralizing a substance in the body called interleukin-18 (IL-18). IL-18 is a key player in the body's inflammatory response. In the conditions that Tadekinig alfa is designed to treat, there's often too much IL-18, leading to excessive inflammation. By binding to IL-18, Tadekinig alfa helps to reduce this inflammation and alleviate symptoms.
How is Tadekinig Alfa Administered?
Tadekinig alfa is given as a subcutaneous injection, which means it's injected just under the skin. The injection sites are typically rotated between the thighs, arms, and abdomen to minimize injection site reactions. The dosage and frequency of administration can vary depending on the specific condition being treated and the individual patient's needs.
Current Clinical Trials
Tadekinig alfa is currently being studied in several clinical trials:
- A Phase 3 study for patients with NLRC4-MAS and XIAP deficiency.
- An open-label extension study to monitor long-term safety and tolerability in patients with NLRC4 mutation and XIAP deficiency.
- A pilot study evaluating its use as a rescue therapy for CAR T-cell related cytokine release syndrome and HLH-like syndrome.
Safety and Side Effects
As with any medication, researchers are closely monitoring the safety of Tadekinig alfa. Common areas of focus include:
- Adverse events (side effects)
- Changes in physical examination findings and vital signs
- Changes in laboratory test results
- Development of antibodies against the medication (immunogenicity)
- Local reactions at the injection site
It's important to note that as Tadekinig alfa is still in clinical trials, not all potential side effects may be known. Patients participating in these trials are closely monitored by healthcare professionals.